Targeting tumor-associated macrophages for cancer immunotherapy

被引：98

作者：

Shu, Yongheng ^{[1
,2
]}

Cheng, Ping ^{[1
,2
]}

机构：

[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 17 Peoples South Rd, Chengdu 610041, Peoples R China

[2] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Canc Ctr, Chengdu 610041, Peoples R China

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2020年 / 1874卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Tumor; Immunotherapy; Tumor-associated macrophages (TAMs); HUMAN MONOCLONAL-ANTIBODY; CHEMOKINE LIGAND 2; CARLUMAB CNTO 888; CAR-T-CELLS; ANTITUMOR-ACTIVITY; SIRP-ALPHA; PHASE-I; MYELOID CELLS; RECEPTOR; ACTIVATION;

D O I：

10.1016/j.bbcan.2020.188434

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Macrophages are important effector cells of the innate immune system and are also major components of the tumor microenvironment (TME). Macrophages that are abundant in the TME are called tumor-associated macrophages (TAMs). As TAMs promote strong tumor angiogenesis and support tumor cell survival, they are closely related to tumor growth. Several studies have demonstrated that reducing the density or effects of TAMs can inhibit the growth of tumors, making them targets for cancer immunotherapy, which has become a research hot spot. Several clinical and preclinical trials have studied drugs that inhibit the effects of and reduce the population of phagocytes that target TAMs achieve cancer immunotherapy. In this paper, we summarize the various methods of targeting TAMs for tumor immunotherapy, focusing on TAM mechanisms, sources, and polarization.

引用

页数：11

共 123 条

[1] Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma [J].

Adelaiye-Ogala, Remi ;

Damayanti, Nur P. ;

Orillion, Ashley R. ;

Arisa, Sreevani ;

Chintala, Sreenivasulu ;

Titus, Mark A. ;

Kao, Chinghai ;

Pili, Roberto .

CANCER RESEARCH, 2018, 78 (11) :2886-2896

[2] CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Flinn, Ian ;

Popplewell, Leslie ;

Forero, Andres ;

Bartlett, Nancy L. ;

Ghosh, Nilanjan ;

Kline, Justin ;

Roschewski, Mark ;

LaCasce, Ann ;

Collins, Graham P. ;

Thu Tran ;

Lynn, Judith ;

Chen, James Y. ;

Volkmer, Jens-Peter ;

Agoram, Balaji ;

Huang, Jie ;

Majeti, Ravindra ;

Weissman, Irving L. ;

Takimoto, Chris H. ;

Chao, Mark P. ;

Smith, Sonali M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) :1711-1721

[3] Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment [J].

Allavena, P. ;

Mantovani, A. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 167 (02) :195-205

[4] SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors [J].

Alvey, Cory M. ;

Spinler, Kyle R. ;

Irianto, Jerome ;

Pfeifer, Charlotte R. ;

Hayes, Brandon ;

Xia, Yuntao ;

Cho, Sangkyun ;

Dingal, P. C. P. Dave ;

Hsu, Jake ;

Smith, Lucas ;

Tewari, Manu ;

Discher, Dennis E. .

CURRENT BIOLOGY, 2017, 27 (14) :2065-+

[5] STING: infection, inflammation and cancer [J].

Barber, Glen N. .

NATURE REVIEWS IMMUNOLOGY, 2015, 15 (12) :760-770

[6] The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target [J].

Barclay, A. Neil ;

van den Berg, Timo K. .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 32, 2014, 32 :25-50

[7] CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy [J].

Barkal, Amira A. ;

Brewer, Rachel E. ;

Markovic, Maxim ;

Kowarsky, Mark ;

Barkal, Sammy A. ;

Zaro, Balyn W. ;

Krishnan, Venkatesh ;

Hatakeyama, Jason ;

Dorigo, Oliver ;

Barkal, Layla J. ;

Weissman, Irving L. .

NATURE, 2019, 572 (7769) :392-+

[8] Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy [J].

Barkal, Amira A. ;

Weiskopf, Kipp ;

Kao, Kevin S. ;

Gordon, Sydney R. ;

Rosental, Benyamin ;

Yiu, Ying Y. ;

George, Benson M. ;

Markovic, Maxim ;

Ring, Nan G. ;

Tsai, Jonathan M. ;

McKenna, Kelly M. ;

Ho, Po Yi ;

Cheng, Robin Z. ;

Chen, James Y. ;

Barkal, Layla J. ;

Ring, Aaron M. ;

Weissman, Irving L. ;

Maute, Roy L. .

NATURE IMMUNOLOGY, 2018, 19 (01) :76-+

[9] A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma [J].

Beatty, Gregory L. ;

Torigian, Drew A. ;

Chiorean, E. Gabriela ;

Saboury, Babak ;

Brothers, Alex ;

Alavi, Abass ;

Troxel, Andrea B. ;

Sun, Weijing ;

Teitelbaum, Ursina R. ;

Vonderheide, Robert H. ;

O'Dwyer, Peter J. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6286-6295

[10] gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis [J].

Bollrath, Julia ;

Phesse, Toby J. ;

von Burstin, Vivian A. ;

Putoczki, Tracy ;

Bennecke, Moritz ;

Bateman, Trudie ;

Nebelsiek, Tim ;

Lundgren-May, Therese ;

Canli, Oezge ;

Schwitalla, Sarah ;

Matthews, Vance ;

Schmid, Roland M. ;

Kirchner, Thomas ;

Arkan, Melek C. ;

Ernst, Matthias ;

Greten, Florian R. .

CANCER CELL, 2009, 15 (02) :91-102

← 1 2 3 4 5 6 7 8 9 10 →